184 related articles for article (PubMed ID: 24573065)
1. Prenatal treatment of Down syndrome: a reality?
Guedj F; Bianchi DW; Delabar JM
Curr Opin Obstet Gynecol; 2014 Apr; 26(2):92-103. PubMed ID: 24573065
[TBL] [Abstract][Full Text] [Related]
2. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.
Guidi S; Stagni F; Bianchi P; Ciani E; Giacomini A; De Franceschi M; Moldrich R; Kurniawan N; Mardon K; Giuliani A; Calzà L; Bartesaghi R
Brain; 2014 Feb; 137(Pt 2):380-401. PubMed ID: 24334313
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
5. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
7. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
[TBL] [Abstract][Full Text] [Related]
8. Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A.
Pons-Espinal M; Martinez de Lagran M; Dierssen M
Neurobiol Dis; 2013 Dec; 60():18-31. PubMed ID: 23969234
[TBL] [Abstract][Full Text] [Related]
9. Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice.
Nakano-Kobayashi A; Awaya T; Kii I; Sumida Y; Okuno Y; Yoshida S; Sumida T; Inoue H; Hosoya T; Hagiwara M
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10268-10273. PubMed ID: 28874550
[TBL] [Abstract][Full Text] [Related]
10. Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.
Guedj F; Siegel AE; Pennings JLA; Alsebaa F; Massingham LJ; Tantravahi U; Bianchi DW
Am J Hum Genet; 2020 Nov; 107(5):911-931. PubMed ID: 33098770
[TBL] [Abstract][Full Text] [Related]
11. DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.
Najas S; Arranz J; Lochhead PA; Ashford AL; Oxley D; Delabar JM; Cook SJ; Barallobre MJ; Arbonés ML
EBioMedicine; 2015; 2(2):120-34. PubMed ID: 26137553
[TBL] [Abstract][Full Text] [Related]
12. Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome.
Altafaj X; Ortiz-Abalia J; Fernández M; Potier MC; Laffaire J; Andreu N; Dierssen M; González-García C; Ceña V; Martí E; Fillat C
Neurobiol Dis; 2008 Dec; 32(3):377-84. PubMed ID: 18773961
[TBL] [Abstract][Full Text] [Related]
13. Prenatal treatment with preimplantation factor improves early postnatal neurogenesis and cognitive impairments in a mouse model of Down syndrome.
Moreau M; Dard R; Madani A; Kandiah J; Kassis N; Ziga J; Castiglione H; Day S; Bourgeois T; Matrot B; Vialard F; Janel N
Cell Mol Life Sci; 2024 May; 81(1):215. PubMed ID: 38739166
[TBL] [Abstract][Full Text] [Related]
14. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
[TBL] [Abstract][Full Text] [Related]
15. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
Valenti D; de Bari L; de Rasmo D; Signorile A; Henrion-Caude A; Contestabile A; Vacca RA
Biochim Biophys Acta; 2016 Jun; 1862(6):1093-104. PubMed ID: 26964795
[TBL] [Abstract][Full Text] [Related]
16. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome.
Guedj F; Bianchi DW
Prenat Diagn; 2013 Jun; 33(6):614-8. PubMed ID: 23595836
[TBL] [Abstract][Full Text] [Related]
18. [New perspectives on molecular and genic therapies in Down syndrome].
Delabar JM
Med Sci (Paris); 2010 Apr; 26(4):371-6. PubMed ID: 20412741
[TBL] [Abstract][Full Text] [Related]
19. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors.
Vink J; Incerti M; Toso L; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2009 May; 200(5):524.e1-4. PubMed ID: 19327737
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome.
Begenisic T; Baroncelli L; Sansevero G; Milanese M; Bonifacino T; Bonanno G; Cioni G; Maffei L; Sale A
Neurobiol Dis; 2014 Mar; 63():12-9. PubMed ID: 24269730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
